Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029070 | 0.88 | GRM4 (0.47) | TAAR1KDM4EGRM4TLR2TLR1 | |
| SCHEMBL1028998 | 0.86 | POLB (0.45) | KDM4EGRM4CYP2C9 | |
| SCHEMBL1074002 | 0.84 | TAAR1 (0.44) | TAAR1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL1028652 | 0.83 | GRM4 (0.41) | KDM4EGRM4CYP2C9SMN1; SMN2HSD17B10 | |
| SCHEMBL1027699 | 0.80 | ALDH1A1 (0.58) | TAAR1CYP2C9SMN1; SMN2F2HSD17B10 | |
| SCHEMBL1029850 | 0.80 | KCNQ3 (0.39) | KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL1027865 | 0.80 | ALDH1A1 (0.35) | — | |
| SCHEMBL1028011 | 0.79 | LMNA (0.36) | KDM4EHSD17B10 | |
| SCHEMBL1025056 | 0.78 | TAAR1 (0.64) | TAAR1HSD17B10 | |
| SCHEMBL1026383 | 0.77 | SLC6A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479669-B1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | TOSOH CORP (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7645889-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7381742-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-7186750-B2 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1479669-A1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | Tosoh Corporation (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | CYBA, COASY, MEP1B | TAAR1 4781/4885KDM4E 2233/4885GRM4 1689/4885 |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, CYBA | TAAR1 4769/4885KDM4E 1805/4885GRM4 1600/4885 |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, ACMSD | TAAR1 4799/4885KDM4E 1750/4885GRM4 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.